Mycophenolate mofetil in primary central nervous system vasculitis

Carlo Salvarani; Robert D Jr. Brown; Teresa J H Christianson; John III Huston; Caterina Giannini; Dylan V. Miller; Francesco Muratore; Gene G. Hunder

doi:10.1016/j.semarthrit.2015.02.008

Mycophenolate mofetil in primary central nervous system vasculitis

Carlo Salvarani, Robert D Jr. Brown, Teresa J H Christianson, John III Huston, Caterina Giannini, Dylan V. Miller, Francesco Muratore, Gene G. Hunder

Research output: Contribution to journal › Article

17 Scopus citations

Abstract

Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.

Original language	English (US)
Pages (from-to)	55-59
Number of pages	5
Journal	Seminars in Arthritis and Rheumatism
Volume	45
Issue number	1
DOIs	https://doi.org/10.1016/j.semarthrit.2015.02.008
State	Published - Aug 1 2015

Keywords

Mycophenolate mofetil
PCNSV
Therapy
Vasculitis

ASJC Scopus subject areas

Rheumatology
Anesthesiology and Pain Medicine

Access to Document

10.1016/j.semarthrit.2015.02.008

Fingerprint Dive into the research topics of 'Mycophenolate mofetil in primary central nervous system vasculitis'. Together they form a unique fingerprint.

Cite this

Salvarani, C., Brown, R. D. J., Christianson, T. J. H., Huston, J. III., Giannini, C., Miller, D. V., Muratore, F., & Hunder, G. G. (2015). Mycophenolate mofetil in primary central nervous system vasculitis. Seminars in Arthritis and Rheumatism, 45(1), 55-59. https://doi.org/10.1016/j.semarthrit.2015.02.008

@article{f64daf8735114c94b69ec76fb4ad33e5,

title = "Mycophenolate mofetil in primary central nervous system vasculitis",

abstract = "Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.",

keywords = "Mycophenolate mofetil, PCNSV, Therapy, Vasculitis",

author = "Carlo Salvarani and Brown, {Robert D Jr.} and Christianson, {Teresa J H} and Huston, {John III} and Caterina Giannini and Miller, {Dylan V.} and Francesco Muratore and Hunder, {Gene G.}",

year = "2015",

month = aug,

day = "1",

doi = "10.1016/j.semarthrit.2015.02.008",

language = "English (US)",

volume = "45",

pages = "55--59",

journal = "Seminars in Arthritis and Rheumatism",

issn = "0049-0172",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Mycophenolate mofetil in primary central nervous system vasculitis

AU - Salvarani, Carlo

AU - Brown, Robert D Jr.

AU - Christianson, Teresa J H

AU - Huston, John III

AU - Giannini, Caterina

AU - Miller, Dylan V.

AU - Muratore, Francesco

AU - Hunder, Gene G.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.

AB - Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.

KW - Mycophenolate mofetil

KW - PCNSV

KW - Therapy

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=84937737529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937737529&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2015.02.008

DO - 10.1016/j.semarthrit.2015.02.008

M3 - Article

C2 - 25800827

AN - SCOPUS:84937737529

VL - 45

SP - 55

EP - 59

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 1

ER -